靶向胶质瘤浸润边缘/切除边缘的新方法
本文综述胶质母细胞瘤(GBM)浸润边缘的独特微环境及当前治疗局限,讨论针对该区域检测与治疗的新进展,以及这些进展可能如何影响患者结局。
要点
- GBM浸润边缘具有免疫抑制、侵袭和治疗抵抗的微环境,血脑屏障基本完整。
- 当前切除范式主要针对对比增强部分,而GBM延伸远超对比增强范围。
- 综述聚焦浸润边缘的检测与治疗进展及其对患者结局的潜在影响。
核心结论
- GBM浸润边缘是治疗难点,也是克服当前治疗局限的独特机会。
研究设计与样本
- 本文为当前文献综述,讨论针对GBM浸润边缘检测与治疗的新进展。
主要发现
- GBM几乎总在边缘或浸润前沿复发,该区域微环境与肿瘤主体或核心不同。
- 浸润边缘含免疫抑制成分及难以治疗的侵袭性和治疗抵抗肿瘤细胞。
- 肿瘤浸润边缘血脑屏障基本完整,进一步限制疗效。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite decades of clinical trials and surgical advances, the most common high-grade glioma, glioblastoma (GBM), remains an incurable disease with a dismal prognosis. Because of its infiltrative nature, GBM almost always recurs at the margin, or leading edge, where tumor cells invade the surrounding brain parenchyma. This region of GBMs is unique, or heterogeneous, with its own microenvironment that is different from the tumor bulk or core. The GBM microenvironment at the margin contains immunosuppressive constituents as well as invasive and therapy-resistant tumor cells that are difficult to treat. In addition, the blood-brain barrier remains essentially intact at the infiltrative margin of tumors; further limiting the effectiveness of therapies. The invasive margin creates the greatest challenge for neurosurgeons when managing these tumors. The current paradigm of resection of GBM tumors mainly focuses on resection of the contrast-enhancing component of tumors, while GBMs extend well beyond the contrast enhancement. The infiltrative margin represents a unique challenge and opportunity for solutions that may overcome current limitations in tumor treatments. In this review of the current literature, the authors discuss the current and developing advances focused on the detection and treatment of GBM at the infiltrative margin and how this could impact patient outcomes.
引用
- Schupper AJ, Hadjipanayis CG. Novel approaches to targeting gliomas at the leading/cutting edge. J Neurosurg. 2023. PMID: 36840741. doi:10.3171/2023.1.JNS221798
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。